Vulvodynia Treatment Market will grow at an impressive CAGR of 6.3% over the period 2022-2028

0

[246 Pages Report] Future Market Insights (FMI) has published a new research report Vulvodynia Treatment Market. The report is titled “Vulvodynia Treatment Market: Global Industry Analysis 2013 – 2021 and Opportunity Assessment 2022 – 2028.” The report states that a recent Harvard study showed that approximately 6 million American women suffer from vulvodynia. Over 60% of patients report having seen three or more healthcare providers for diagnosis, and a staggering 40% of patients remain undiagnosed. This study also reported that 40% of women with painful symptoms did not even see a doctor. Associations such as the National Vulvodynia Association (NVA) play an important role in spreading awareness of the management of vulvodynia. The NVA announced the launch of Indivisible: Breaking the Silence, a campaign to empower women with vulvodynia to break their silence and improve the path to diagnosis and treatment.

To meet the needs of the growing number of patients, companies are looking for treatments and medications that can alleviate the pain associated with vulvodynia. To do this, they invest in research and development as well as in mergers and acquisitions. For example, in January 2016, Merck & Co. Inc. acquired IOmet Pharma Ltd., a privately held UK drug discovery company focused on developing innovative drugs to treat cancer. The other leading companies operating in the market include Eli Lilly and Company, AstraZeneca Plc., GlaxoSmithKline Plc., Pfizer Inc., Johnson & Johnson Services, Inc. and Allergan plc.

According to the report, the global vulvodynia treatment market is expected to register a CAGR of 6.1% during the forecast period 2022 and 2028. The market was worth $4,261.2Mn in 2021 and is expected to reach $8,091.6Mn by the end of 2028.

To get ahead of your competitors, request a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-4985

Growing adoption bodes well for global market revenue growth

The growing number of patients suffering from vulvodynia and the harsh nature of chronic vulvar pain have led to early diagnosis and treatment. The reasonable outcomes of medical treatments such as drugs, injections, and creams have increased the preference for drugs to treat vulvodynia. In addition, the increasing adoption of drug treatments for vulvodynia has led to an increase in sales of hormones, local anesthetics and antidepressants. Furthermore, promising reimbursement policies in most developed countries are also expected to act as value drivers for the growth of the global vulvodynia treatment market. On the other hand, the growing prevalence of vulvodynia disease among women across the world is a key factor driving the growth of vulvodynia treatment market. Vulvodynia is a very common disease in the United States and around the world. However, the condition remains underdiagnosed or, in some cases, incompetently treated.

Lethargic R&D for Vulvodynia Treatment Drugs to Slow Market Growth

Due to the lack of detailed information by the patients, ignorance of the cause of vulvar pain, and the satisfactory results of anticonvulsant drugs and tricyclic antidepressants, researchers are unable to uncover the exact cause of vulvodynia, and hence the research and development of vulvodynia drugs limited. After anticonvulsants and tricyclic antidepressants, only serotonin and norepinephrine reuptake inhibitors (SNRIs) have shown positive results. In addition, vulvodynia treatment research and development, if you watch it, is also at a very sluggish stage.

Get a customized report that suits your needs, Ask the Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-4985

Key Segments of Vulvodynia Treatment Industry SurveyVulvodynia Treatment Market by drug class:
  • local anesthetics
  • anticonvulsant
  • Tricyclic antidepressants
  • hormones
  • Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)
  • nerve blocks
  • Other

Vulvodynia Treatment Market by Application Type:

  • Oral vulvodynia treatment
  • Topical vulvodynia treatment
  • Injection Vulvodynia Treatment

Vulvodynia Treatment Market by Distribution Channel:

  • hospital pharmacies
  • retail pharmacies
  • drugstore
  • online pharmacies

About Future Market Insights (FMI)
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. Headquartered in Dubai, FMI has delivery centers in the UK, US and India. FMI’s latest market research reports and industry analysis help companies overcome challenges and make important decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert analysts at FMI continuously follows emerging trends and events across a variety of industries to ensure our clients prepare for the evolving needs of their consumers.

Contact:
future market insights,
1602-6 Jumeirah Bay X2 Tower,
Plot No.: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
For sales inquiries: [email protected]
For media inquiries: [email protected]
Website: https://www.futuremarketinsights.com/

The Post-Vulvodynia Treatment Market will grow at an impressive CAGR of 6.3% over the period 2022-2028, appeared first on Future Market Insights.

Share.

Comments are closed.